SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 82.58 percent increase over losses of $(3.96) per share from the same period last year.